Pharming Group N.V.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Pharming Group N.V.
“A lot of companies are hurting because of the higher interest rates,” one major CEO observed recently, summing up a year which saw little headline-grabbing news on the M&A front for generic and biosimilar sponsors.
Heart disease seems impervious to cell therapy approaches. Is biomarker stratification the answer?
ORM-6151 combines two hot approaches in cancer R&D, but clinical trials have not yet started.
Merck’s 21-valent pneumococcal conjugate vaccine for older adults could see US FDA approval in H1 2024, opening up another level of complexity for the CDC’s vaccine recommendations.
- Drug Discovery Tools
- Large Molecule
- Synthesis Technologies, Production Processes
Drug Discovery Tools
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.